Glenmark gets USFDA nod for generic diabetes treatment drug

The approval is for strengths of 0.1 mg and 0.2 mg and the company plans to commence shipping the tablets to the US immediately

Glenmark Pharmaceuticals today said it has received the final approval from US health regulator for its generic version of desmopressin acetate tablets used in treatment of diabetes and bed-wetting.

The approval by the US Food and Drug Administration (USFDA) is for strengths of 0.1 mg and 0.2 mg and the company plans to commence shipping the tablets to the US immediately, the pharma company said in a statement.

Desmopressin Acetate is sold under the trademark DDAVP by Ferring Pharmaceuticals. Citing IMS data, Glenmark said, "DDAVP market achieved annual sales of approximately USD 72.1 million" in the 12 month period ended March 2015.

Glenmark's current portfolio consists of 97 products authorised for distribution in the US and 68 abbreviated new drug approvals with the USFDA.

Shares of Glenmark Pharmaceuticals were trading at Rs 874.75 per scrip in afternoon trade, up 2.04 per cent from the previous close on the BSE.